Pioneer's FortrOss bone filler receives FDA clearance
This article was originally published in Clinica
Executive Summary
Pioneer Surgical Technology's FortrOss bone graft substitute has received US FDA 510(k) clearance. The scaffold, which is used for the in-growth of bone and other connective tissues, combines the firm's NanOss nanotechnology material (originally developed by Angstrom Medica) and the osteoprotective E-Matrix scaffold, from Encelle. Marquette, Michigan-based Pioneer acquired Encelle in June 2007 and Angstrom in October 2007 (see Clinica Nos 1259, p 18 & 1280, p 15). Pioneer claims that FortrOss is the most advanced bone filler on the market, as it is designed to mimic human bone tissue. This means that bone cells recognise it as native tissue and have a high affinity for it.